Telormedix, a clinical stage biopharmaceutical company focussed on TLR7
agonists in the treatment of cancer and infectious diseases, has been
granted the European Patent No. 2393474 entitled "Pharmaceutical
compositions comprising imidazoquinolin (amines) and derivatives thereof
suitable for local administration" by the European Patent Office.
The European patent, which will expire in 2030, broadly covers Telormedix’s lead product Vesimune (TMX-101) and its use for the treatment of bladder cancer. Further patents for Telormedix’s Vesimune have also recently been granted in China and Australia.
,Vesimune is Telormedix’s lead product, a TLR-7 agonist currently has successfully completed a phase II trial in CIS (carcinoma in situ) of the bladder. The product is a unique sterile liquid formulation of a marketed immune modulatory compound, designed on innovative technology principles to carrier drug delivery systems in order to increase solubility, bio-adhesiveness and stability. These properties mean that the product can be used in therapeutic settings that the original product could not.
The European patent, which will expire in 2030, broadly covers Telormedix’s lead product Vesimune (TMX-101) and its use for the treatment of bladder cancer. Further patents for Telormedix’s Vesimune have also recently been granted in China and Australia.
,Vesimune is Telormedix’s lead product, a TLR-7 agonist currently has successfully completed a phase II trial in CIS (carcinoma in situ) of the bladder. The product is a unique sterile liquid formulation of a marketed immune modulatory compound, designed on innovative technology principles to carrier drug delivery systems in order to increase solubility, bio-adhesiveness and stability. These properties mean that the product can be used in therapeutic settings that the original product could not.
No comments:
Post a Comment